Literature DB >> 23835446

Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Kanakatte Raviprakash1, Peifang Sun, Yossef Raviv, Thomas Luke, Nicholas Martin, Tadeusz Kochel.   

Abstract

Two novel methods of dengue virus inactivation using iodonaphthyl azide (INA) and aminomethyl trioxsalen (AMT) were compared with traditional virus inactivation by formaldehyde. The AMT inactivated dengue-2 virus retained its binding to a panel of 5 monoclonal antibodies specific for dengue-2 envelope protein, whereas inactivation by formaldehyde and INA led to 30-50% decrease in binding. All three inactivated viruses elicited high level virus neutralizing antibodies in vaccinated mice. However, only mice vaccinated with AMT inactivated virus mounted T cell responses similar to live, uninactivated virus.

Entities:  

Keywords:  dengue virus; immunogenicity; mouse; vaccine; virus inactivation

Mesh：

Substances：

Year:  2013        PMID： 23835446      PMCID： PMC3981842          DOI： 10.4161/hv.25602

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  35 in total

1.  Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

Authors:  Robert Edelman; Steven S Wasserman; Sacared A Bodison; Robert J Putnak; Kenneth H Eckels; Douglas Tang; Niranjan Kanesa-Thasan; David W Vaughn; Bruce L Innis; Wellington Sun
Journal:  Am J Trop Med Hyg       Date:  2003-12       Impact factor: 2.345

2.  Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness.

Authors:  S Kliks
Journal:  AIDS Res Hum Retroviruses       Date:  1990-08       Impact factor: 2.205

3.  Photochemical inactivation of DNA and RNA viruses by psoralen derivatives.

Authors:  C V Hanson; J L Riggs; E H Lennette
Journal:  J Gen Virol       Date:  1978-08       Impact factor: 3.891

4.  Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation.

Authors:  J T Mason; T J O'Leary
Journal:  J Histochem Cytochem       Date:  1991-02       Impact factor: 2.479

5.  A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.

Authors:  Kanakatte Raviprakash; Thomas Luke; John Doukas; Janine Danko; Kevin Porter; Timothy Burgess; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

6.  Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.

Authors:  S C Kliks; A Nisalak; W E Brandt; L Wahl; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1989-04       Impact factor: 2.345

Review 7.  Review of accidents caused by incomplete inactivation of viruses.

Authors:  F Brown
Journal:  Dev Biol Stand       Date:  1993

8.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

9.  Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.

Authors:  R Putnak; D A Barvir; J M Burrous; D R Dubois; V M D'Andrea; C H Hoke; J C Sadoff; K H Eckels
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

10.  Hepatitis and hepatitis A vaccine: a glimpse of history.

Authors:  M R Hilleman
Journal:  J Hepatol       Date:  1993       Impact factor: 25.083
View more
  9 in total

1.  Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.

Authors:  Shuenn-Jue Wu; Dan Ewing; Appavu K Sundaram; Hua-Wei Chen; Zhaodong Liang; Ying Cheng; Vihasi Jani; Peifang Sun; Gregory D Gromowski; Rafael A De La Barrera; Megan A Schilling; Nikolai Petrovsky; Kevin R Porter; Maya Williams
Journal:  Microorganisms       Date:  2022-05-16

2.  Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.

Authors:  Taweewun Hunsawong; Panya Sunintaboon; Saradee Warit; Butsaya Thaisomboonsuk; Richard G Jarman; In-Kyu Yoon; Sukathida Ubol; Stefan Fernandez
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

3.  Inactivation of non-enveloped virus by 1,5 iodonaphthyl azide.

Authors:  Paridhi Gupta; Anuj Sharma; Viard Mathias; Yossef Raviv; Robert Blumenthal; Radha K Maheshwari
Journal:  BMC Res Notes       Date:  2015-02-15

4.  Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections.

Authors:  Cecilia Gómez-Calderón; Carol Mesa-Castro; Sara Robledo; Sergio Gómez; Santiago Bolivar-Avila; Fredyc Diaz-Castillo; Marlen Martínez-Gutierrez
Journal:  BMC Complement Altern Med       Date:  2017-01-18       Impact factor: 3.659

5.  Photochemical Treatment of Drosophila APCs Can Eliminate Associated Viruses and Maintain the APC Function for Generating Antigen-Specific CTLs Ex Vivo.

Authors:  Jun Ye; Chunxia Yang; Zeling Cai; Weixing Shi; Hong Yu
Journal:  Mediators Inflamm       Date:  2018-09-20       Impact factor: 4.711

6.  Inactivation of Zika Virus by Photoactive Iodonaphthyl Azide Preserves Immunogenic Potential of the Virus.

Authors:  Amy L Austin; Bianca Galasso; Caitlin Nickens; Barbara Knollmann-Ritschel; Anuj Sharma
Journal:  Pathogens       Date:  2019-10-12

Review 7.  Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes.

Authors:  Simon Elveborg; Vanessa M Monteil; Ali Mirazimi
Journal:  Pathogens       Date:  2022-02-19

8.  Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid.

Authors:  Katherine Schneider; Loni Wronka-Edwards; Melissa Leggett-Embrey; Eric Walker; Peifang Sun; Brian Ondov; Travis H Wyman; M J Rosovitz; Sherry S Bohn; James Burans; Tadeusz Kochel
Journal:  Viruses       Date:  2015-11-12       Impact factor: 5.048

9.  Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.

Authors:  Appavu K Sundaram; Daniel Ewing; Zhaodong Liang; Vihasi Jani; Ying Cheng; Peifang Sun; Kanakatte Raviprakash; Shuenn-Jue Wu; Nikolai Petrovsky; Gabriel Defang; Maya Williams; Kevin R Porter
Journal:  Pathogens       Date:  2021-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.